title: WIN OVER study: Efficacy and safety of olmesartan in Indian hypertensive patients: results of an open label, non-comparative, multi-centric, post marketing observational study.
abstract: BACKGROUND
  Hypertension is a global health problem. Multiple classes of drugs including angiotensin receptor blockers (ARBs) are available for the treatment of hypertension. Olmesartan is a relatively newer ARB used in hypertension management.
  
  
  OBJECTIVE
  To assess the efficacy and safety of WIN-BP (Olmesartan 20 mg/40 mg) tablet in Indian patients with hypertension.
  
  
  METHODS
  An open label, non-comparative, multi-centric, real world post marketing observational study included Indian adult hypertensive patients who were treated with olmesartan 20 mg/40 mg tablet once daily for six months. The primary outcome was reduction of systolic blood pressure (SBP) to <140 mmHg and diastolic BP (DBP) to <90 mmHg at 3 and 6 months after initiation of treatment with olmesartan. All reported adverse events were recorded.
  
  
  RESULTS
  A total of 8940 patients were enrolled in this study. Baseline SBP of 164 mmHg was reduced to 153, 145, 134 and 130 mmHg at the end of 15 days, 1, 3 and 6 months respectively. Similarly, baseline DBP of 100 mmHg was reduced to 93, 89, 84 and 82 mmHg at the end of 15 days, 1, 3 and 6 months respectively. The reduction in both systolic and diastolic blood pressure from day 15 to month 6 was statistically significant (p < 0.0001) with olmesartan treatment. The percentage of responders for both systolic and diastolic blood pressure increased consistently from day 15 to month 6. Only 0.08% patients reported the adverse events. No serious adverse event was reported in the study.
  
  
  CONCLUSIONS
  Olmesartan 20 mg/40 mg is effective and well tolerated without any serious adverse events in patients with hypertension.
authors: Consultant Clinical & Interventional Cardiologist, Jupiter Hospital, Thane, India.
authors: D K
authors: DK
authors: Kumbla
authors: Consultant Cardiologist, AMRI Hospital, Kolkata, India.
authors: S
authors: S
authors: Kumar
authors: Consultant Cardiologist, Chennai, India.
authors: Y V
authors: YV
authors: Reddy
authors: Manager, Medical Advisor, Medical Services Division, Abbott Healthcare Private Limited, Mumbai, India. Electronic address: abhijit.trailokya@abbott.in.
authors: A
authors: A
authors: Trailokya
authors: Chief Manager, Medical Services, Abbott Healthcare Private Limited, Mumbai, India.
authors: M
authors: M
authors: Naik
mesh_terms: D000328:Adult; D005260:Female; D006801:Humans; D008297:Male; D000284:Administration, Oral; D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage; D001794:Blood Pressure / Q000187:drug effects / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology; D007093:Imidazoles / Q000008:administration & dosage; D011358:Product Surveillance, Postmarketing / Q000379:methods; D013777:Tetrazoles / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D007093:Imidazoles; C437965:olmesartan; D013777:Tetrazoles
keywords: Efficacy; Hypertension; Olmesartan; Safety